Nestle (SIX:NESN) stock dipped about 1% after Barclays analysts lowered their forecast for the Swiss food group's second-quarter organic sales growth, flagging a challenging environment for U.S. consumers and retailers.
In its updated outlook, Barclays trimmed its Q2 organic sales growth estimate to 3.7% from 4.0%, citing continued headwinds in the U.S. market. The bank noted that, while Nestle’s petfood and coffee businesses delivered solid performances in the first quarter, the broader U.S. backdrop remains difficult for the company.
Barclays is looking to real internal growth (RIG) of 2% or higher as the key metric for the upcoming quarter, expecting this figure to matter more as pricing benefits begin to fade. The firm underlined that Nestle’s pricing advantage is diminishing and that underlying volume and mix-driven growth will be the focus.
The company is due to release first-half 2026 results on July 23. Barclays expects the second quarter to show a smaller negative effect from Nestle’s infant formula recall than was seen in the first quarter. The recall had produced a 90 basis point drag on organic sales growth in Q1; Barclays remarked that roughly half of that impact was one-time in nature due to stock outs.
Management’s guidance indicates the recall will subtract about 30-40 basis points at the group level for the year. Barclays’ commentary suggests that the worst of the immediate sales disruption from the recall is likely behind Nestle, but residual effects are still expected to affect 2026 figures.
Separately, Nestle’s operations in China are set to face easier year-over-year comparisons in Q2 after a reset in the second quarter of 2025. The company has shifted its China approach from a distribution-push model to a consumer-pull model, and the business has been down roughly 10% on average over the last four quarters as a result of that transition. The second quarter of 2026 will be the first period in which the reset’s effect is embedded in the comparison base.
Nestle continues to guide for full-year 2026 organic sales growth of approximately 3-4%. Management expects an increasing contribution from real internal growth as pricing rolls over through the year.
Context for investors
Barclays’ revision and commentary encapsulate several dynamics investors will want to watch as Nestle moves through the remainder of 2026: the durability of demand in the U.S., the pace at which pricing turns into volume-driven growth, and the normalization of sales following the infant formula recall. The timing of the company’s July 23 results will provide the next formal update on these items.